The objective of the present invention is to provide a compound which has V2 receptor agonistic activity. A pharmaceutical composition which contains, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In general formula (I), R1 represents a group represented by formula (2) or the like； R2 represents a hydrogen atom or a lower alkyl group； R3 represents a lower alkyl group which may be substituted by 1-3 fluorine atoms, or a halogen atom； R4 represents a five-membered aromatic monocyclic heterocyclic group, a five-membered non-aromatic monocyclic heterocyclic group or the like (provided that these heterocyclic groups have at least one nitrogen atom and may be substituted by a lower alkyl group)； and R5 represents a lower alkyl group, a halogen atom or the like.) (In formula (2), A represents a lower alkylene group which may be substituted by a lower alkyl group, or the like； R6 represents a hydrogen atom or the like； and R7 represents a hydroxyl group, an aromatic heterocyclic group which may be substituted by a lower alkyl group, a carbamoyl group or the like.)
